Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients (DOPPIO): Protocol for a Prospective Multicenter Study

Overview

Journal JMIR Res Protoc

Publisher JMIR Publications

Specialty General Medicine

Date 2023 Jul 12

PMID 37436797

Authors

Sibylle Mellinghoff

Gero von Gersdorff

Caroline Bruns

Kerstin Albus

Vassiliki Dimitriou

Angela Steinbach

Mathias Schaller

Jorg Janne Vehreschild

Oliver A Cornely

Blasius Janusch Liss

Affiliations

Soon will be listed here.

Abstract

Background: Pneumonia is a leading cause of death in patients with end-stage chronic kidney disease treated with dialysis. Current vaccination schedules recommend pneumococcal vaccination. However, this schedule disregards findings of rapid titer decline in adult hemodialysis patients after 12 months.

Objective: The primary objective is to compare pneumonia rates between recently vaccinated patients and patients vaccinated more than 2 years ago. As an exploratory objective, antipneumococcal antibody titers in hemodialysis patients will be determined as a function. Factors influencing antibody kinetics will be identified.

Methods: Within this prospective multicenter study, we aim to compare 2 strata of vaccinated patients: those recently vaccinated and those vaccinated more than 2 years ago. A total of 792 patients will be enrolled. Twelve partner sites (within the German Centre for Infection Research [DZIF]) with allocated dialysis practices participate in this study. All dialysis patients who are vaccinated against pneumococcal infection in accordance with Robert Koch Institute guidelines prior to enrollment will be eligible. Data on baseline demographics, vaccination history, and underlying disease will be assessed. Pneumococcal antibody titers will be determined at baseline and every 3 months for 2 years. DZIF clinical trial units coordinate titer assessment schedules and actively follow-up on study patients for 2-5 years after enrollment, including validation of end points of hospitalization, pneumonia, and death.

Results: The study has enrolled 792 patients and the last follow-up has been completed. Currently, the statistical and laboratory analyses are ongoing.

Conclusions: Results will increase physician adherence to current recommendations. Establishing a framework for the efficient evaluation of guideline recommendations through a combination of routine and study data will inform the evidence base for future guidelines.

Trial Registration: ClinicalTrials.gov NCT03350425; https://clinicaltrials.gov/ct2/show/NCT03350425.

International Registered Report Identifier (irrid): DERR1-10.2196/45712.

References

Jain S, Self W, Wunderink R, Fakhran S, Balk R, Bramley A . Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015; 373(5):415-27. PMC: 4728150. DOI: 10.1056/NEJMoa1500245. View

Bonten M, Huijts S, Bolkenbaas M, Webber C, Patterson S, Gault S . Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372(12):1114-25. DOI: 10.1056/NEJMoa1408544. View

Musher D, Abers M, Bartlett J . Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus. Clin Infect Dis. 2017; 65(10):1736-1744. PMC: 7108120. DOI: 10.1093/cid/cix549. View

Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J . US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2015; 66(1 Suppl 1):Svii, S1-305. PMC: 6643986. DOI: 10.1053/j.ajkd.2015.05.001. View

Diao W, Shen N, Yu P, Liu B, He B . Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016; 34(13):1496-1503. DOI: 10.1016/j.vaccine.2016.02.023. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

Rubin L, Levin M, Ljungman P, Davies E, Avery R, Tomblyn M . 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2013; 58(3):e44-100. DOI: 10.1093/cid/cit684. View

Restrepo M, Mortensen E, Velez J, Frei C, Anzueto A . A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2007; 133(3):610-7. DOI: 10.1378/chest.07-1456. View

Guo H, Liu J, Collins A, Foley R . Pneumonia in incident dialysis patients--the United States Renal Data System. Nephrol Dial Transplant. 2007; 23(2):680-6. DOI: 10.1093/ndt/gfm474. View

10.

Gadsby N, Russell C, McHugh M, Mark H, Morris A, Laurenson I . Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis. 2016; 62(7):817-823. PMC: 4787606. DOI: 10.1093/cid/civ1214. View

11.

Bond T, Spaulding A, Krisher J, McClellan W . Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis. 2012; 60(6):959-65. DOI: 10.1053/j.ajkd.2012.04.018. View

12.

Robinson J . Efficacy of pneumococcal immunization in patients with renal disease--what is the data?. Am J Nephrol. 2004; 24(4):402-9. DOI: 10.1159/000079883. View

13.

Murray C, Vos T, Lozano R, Naghavi M, Flaxman A, Michaud C . Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2197-223. DOI: 10.1016/S0140-6736(12)61689-4. View

14.

Musher D, Roig I, Cazares G, Stager C, Logan N, Safar H . Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect. 2013; 67(1):11-8. PMC: 7132393. DOI: 10.1016/j.jinf.2013.03.003. View

15.

Vandecasteele S, Ombelet S, Blumental S, Peetermans W . The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease. Clin Kidney J. 2015; 8(3):318-24. PMC: 4440476. DOI: 10.1093/ckj/sfv030. View

16.

Gilbertson D, Guo H, Arneson T, Collins A . The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrol Dial Transplant. 2011; 26(9):2934-9. DOI: 10.1093/ndt/gfq853. View

17.

Pourfarziani V, Ramezani M, Taheri S, Izadi M, Einollahi B . Immunogenicity of pneumococcal vaccination in renal transplant recipients and hemodialysis patients: a comparative controlled trial. Ann Transplant. 2008; 13(3):43-7. View

18.

Caskey F, Schober-Halstenberg H, Roderick P, Edenharter G, Ansell D, Frei U . Exploring the differences in epidemiology of treated ESRD between Germany and England and Wales. Am J Kidney Dis. 2006; 47(3):445-54. DOI: 10.1053/j.ajkd.2005.12.026. View

19.

Linnemann Jr C, First M, Schiffman G . Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med. 1986; 146(8):1554-6. View